Stereotactic Body Radiotherapy for Primary Hepatic Malignancies - Report of a Phase I/II Institutional Study

Overview

Journal Radiother Oncol

Specialties Oncology
Radiology

Date 2016 Aug 28

PMID 27566894

Citations 39

Authors

Ashley A Weiner

Jeffrey Olsen

Daniel Ma

Pawel Dyk

Todd DeWees

Robert J Myerson

Parag Parikh

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: To report outcomes and toxicities of a single-institution phase I/II study of stereotactic body radiotherapy (SBRT) in the treatment of unresectable hepatocellular cancer (HCC) and intrahepatic cholangiocarcinoma (IHC).

Materials And Methods: Patients with Child-Pugh score less than 8 were eligible. A total of 32 lesions in 26 patients were treated with SBRT. Kaplan-Meier survival analysis was performed. Toxicities were graded by CTCAEv4 criteria and response was scored by EASL guidelines.

Results: Median prescribed dose was 55Gy (range 40-55Gy) delivered in 5 fractions. Mean tumor diameter was 5.0cm and mean GTV was 107cc. Median follow-up was 8.8months with a median survival of 11.1months, and one-year overall survival was 45%. Overall response rate was 42% and one-year local control was 91%. Nine patients experienced a decline in Child-Pugh class following treatment, and two grade 5 hepatic failure toxicities occurred during study follow-up.

Conclusions: Primary hepatic malignancies not amenable to surgical resection portend a poor prognosis, despite available treatment options. Though radiation-induced liver disease (RILD) is rare following SBRT, this study demonstrates a risk of hepatic failure despite adherence to protocol constraints.

Citing Articles

Interventional Radiology Locoregional Therapies for Intrahepatic Cholangiocarcinoma.

Woodhead G, Lee S, Struycken L, Goldberg D, Hannallah J, Young S Life (Basel). 2024; 14(2).

PMID: 38398726 PMC: 10890186. DOI: 10.3390/life14020217.

Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?.

Bourien H, Pircher C, Guiu B, Lamarca A, Valle J, Niger M Cancers (Basel). 2023; 15(17).

PMID: 37686493 PMC: 10486617. DOI: 10.3390/cancers15174217.

Clinical outcomes of patients with unresectable primary liver cancer treated with MR-guided stereotactic body radiation Therapy: A Six-Year experience.

Chin R, Schiff J, Bommireddy A, Kang K, Andruska N, Price A Clin Transl Radiat Oncol. 2023; 41:100627.

PMID: 37441543 PMC: 10334127. DOI: 10.1016/j.ctro.2023.100627.

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma.

J Liver Cancer. 2023; 23(1):1-120.

PMID: 37384024 PMC: 10202234. DOI: 10.17998/jlc.2022.11.07.

Locoregional Therapy for Intrahepatic Cholangiocarcinoma.

Owen M, Makary M, Beal E Cancers (Basel). 2023; 15(8).

PMID: 37190311 PMC: 10137284. DOI: 10.3390/cancers15082384.

References

Tse R, Hawkins M, Lockwood G, Kim J, Cummings B, Knox J . Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Clin Oncol. 2008; 26(4):657-64. DOI: 10.1200/JCO.2007.14.3529. View

Huang J, DeWees T, Badiyan S, Speirs C, Mullen D, Fergus S . Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma. Int J Radiat Oncol Biol Phys. 2015; 92(5):1000-1007. DOI: 10.1016/j.ijrobp.2015.04.005. View

Dyk P, Weiner A, Badiyan S, Myerson R, Parikh P, Olsen J . Effect of high-dose stereotactic body radiation therapy on liver function in the treatment of primary and metastatic liver malignancies using the Child-Pugh score classification system. Pract Radiat Oncol. 2014; 5(3):176-182. DOI: 10.1016/j.prro.2014.09.007. View

Mendez Romero A, Wunderink W, Hussain S, de Pooter J, Heijmen B, Nowak P . Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol. 2006; 45(7):831-7. DOI: 10.1080/02841860600897934. View

Parkin D, Bray F, Ferlay J, Pisani P . Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55(2):74-108. DOI: 10.3322/canjclin.55.2.74. View

Scorsetti M, Comito T, Cozzi L, Clerici E, Tozzi A, Franzese C . The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT). J Cancer Res Clin Oncol. 2015; 141(7):1301-9. DOI: 10.1007/s00432-015-1929-y. View

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Culleton S, Jiang H, Haddad C, Kim J, Brierley J, Brade A . Outcomes following definitive stereotactic body radiotherapy for patients with Child-Pugh B or C hepatocellular carcinoma. Radiother Oncol. 2014; 111(3):412-7. DOI: 10.1016/j.radonc.2014.05.002. View

Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael R . Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014; 89(5):1084-1091. DOI: 10.1016/j.ijrobp.2014.04.025. View

10.

Llovet J, Fuster J, Bruix J . Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 30(6):1434-40. DOI: 10.1002/hep.510300629. View

11.

Bujold A, Massey C, Kim J, Brierley J, Cho C, Wong R . Sequential phase I and II trials of stereotactic body radiotherapy for locally advanced hepatocellular carcinoma. J Clin Oncol. 2013; 31(13):1631-9. DOI: 10.1200/JCO.2012.44.1659. View

12.

Feng M, Ben-Josef E . Radiation therapy for hepatocellular carcinoma. Semin Radiat Oncol. 2011; 21(4):271-7. DOI: 10.1016/j.semradonc.2011.05.002. View

13.

Vallet-Pichard A, Rerolle J, Fontaine H, Larousserie F, Peraldi M, Kreis H . Veno-occlusive disease of the liver in renal transplant patients. Nephrol Dial Transplant. 2003; 18(8):1663-6. DOI: 10.1093/ndt/gfg222. View

14.

Schefter T, Kavanagh B, Timmerman R, Cardenes H, Baron A, Gaspar L . A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastases. Int J Radiat Oncol Biol Phys. 2005; 62(5):1371-8. DOI: 10.1016/j.ijrobp.2005.01.002. View

15.

Andolino D, Johnson C, Maluccio M, Kwo P, Tector A, Zook J . Stereotactic body radiotherapy for primary hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81(4):e447-53. DOI: 10.1016/j.ijrobp.2011.04.011. View

16.

Lario M, Munoz L, Ubeda M, Borrero M, Martinez J, Monserrat J . Defective thymopoiesis and poor peripheral homeostatic replenishment of T-helper cells cause T-cell lymphopenia in cirrhosis. J Hepatol. 2013; 59(4):723-30. DOI: 10.1016/j.jhep.2013.05.042. View

17.

Kopek N, Holt M, Hansen A, Hoyer M . Stereotactic body radiotherapy for unresectable cholangiocarcinoma. Radiother Oncol. 2009; 94(1):47-52. DOI: 10.1016/j.radonc.2009.11.004. View

18.

Goodman K, Wiegner E, Maturen K, Zhang Z, Mo Q, Yang G . Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010; 78(2):486-93. DOI: 10.1016/j.ijrobp.2009.08.020. View

19.

Son S, Choi B, Ryu M, Kang Y, Jang J, Bae S . Stereotactic body radiotherapy for patients with unresectable primary hepatocellular carcinoma: dose-volumetric parameters predicting the hepatic complication. Int J Radiat Oncol Biol Phys. 2010; 78(4):1073-80. DOI: 10.1016/j.ijrobp.2009.09.009. View

20.

Dawson L, Normolle D, Balter J, McGinn C, Lawrence T, Ten Haken R . Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002; 53(4):810-21. DOI: 10.1016/s0360-3016(02)02846-8. View